Indranil Banerjee

Indranil Banerjee


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2018 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
CDChandan Kanta Das
Chandan Kanta Das
BJBikash Chandra Jena
Bikash Chandra Jena
IBIndranil Banerjee
Indranil Banerjee
SDSubhayan Das
Subhayan Das
APAditya Parekh
Aditya Parekh
MMMahitosh Mandal
Mahitosh Mandal

1 July 2016 in Acta Biomaterialia
Verified
Journal Article
Closed access
IBIndranil Banerjee
Indranil Banerjee
KDKakali De
Kakali De
DMDibyanti Mukherjee
Dibyanti Mukherjee
GDGoutam Dey
Goutam Dey
SCSankha Chattopadhyay
Sankha Chattopadhyay
MMMridula Misra
Mridula Misra

1 March 2017 in Cancer Letters
Verified
Journal Article
Closed access
RBRashmi Bharti
Rashmi Bharti
GDGoutam Dey
Goutam Dey
IBIndranil Banerjee
Indranil Banerjee
KDKaushik Kumar Dey
Kaushik Kumar Dey
SPSheetal Parida
Sheetal Parida
MMMahitosh Mandal
Mahitosh Mandal

1 November 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
CDChandan Kanta Das
Chandan Kanta Das
IBIndranil Banerjee
Indranil Banerjee
MMMahitosh Mandal
Mahitosh Mandal

1 March 2018 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
MDManjarika De
Manjarika De
SGSneha Ghosh
Sneha Ghosh
TSTriparna Sen
Triparna Sen
MSMd. Shadab
Md. Shadab
IBIndranil Banerjee
Indranil Banerjee
Nahid AliNahid Ali
Nahid Ali
There is a pressing need for a ubiquitously expressed antigen or receptor on the tumor surface for successful mitigation of the deleterious side effects of chemotherapy. Phosphatidylserine (PS), normally constrained to the intracellular surface, is exposed on the external surface of tumors and most tumorigenic cell lines. Here we report that a novel PS-targeting liposome, phosphatidylcholine-stearylamine (PC-SA), induced apoptosis and showed potent anticancer effects as a single agent against a majority of cancer cell lines. We experimentally proved that this was due to a strong affinity for and direct interaction of these liposomes with PS. Complexation of the chemotherapeutic drugs doxorubicin and camptothecin in these vesicles demonstrated a manyfold enhancement in the efficacies of the drugs both in vitro and across three advanced tumor models without any signs of toxicity. Both free and drug-loaded liposomes were maximally confined to the tumor site with low tissue concentration. These data indicate that PC-SA is a unique and promising liposome that, alone and as a combination therapy, has anticancer potential across a wide range of cancer types.

14 May 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YRYetirajam Rajesh
Yetirajam Rajesh
ABAngana Biswas
Angana Biswas
UKUtkarsh Kumar
Utkarsh Kumar
IBIndranil Banerjee
Indranil Banerjee
SDSubhayan Das
Subhayan Das
Paul FisherPaul Fisher
Paul Fisher
Significance: No current therapies prevent recurrence in patients with glioblastoma multiforme (GBM). Extracellular matrix (ECM) remodeling and epithelial mesenchymal transition (EMT) are important processes regulating GBM progression and acquisition of radiation and temozolomide (radio/TMZ) resistance. Fli-1 choreographs ECM remodeling and EMT in GBM via transcriptional regulation of HSPB1. Lumefantrine, an antimalarial drug, inhibits the transcriptional activities of Fli-1 and its downstream targets HSPB1, ECM remodeling, and EMT. Lumefantrine is selectively cytotoxic and promotes apoptosis in GBM and reverses radio/TMZ resistance in GBM. This drug can easily be repurposed for management of GBM. Identification of drugs like lumefantrine from FDA-approved therapeutic agents and uncommon sources provides opportunities to broaden the breadth and versatility of current therapeutic regimens for GBM.